Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | LTA4H | P09960 | 7/20 | 0.45 |
| ▸ | HTR1A | P08908 | 1/20 | 0.45 |
| ▸ | HTR1D | P28221 | 1/20 | 0.45 |
| ▸ | HTR2A | P28223 | 1/20 | 0.45 |
| ▸ | HRH1 | P35367 | 1/20 | 0.45 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
| ▸ | MERTK | Q12866 | 1/20 | 0.43 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.40 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.40 |
| ▸ | CACNB1 | Q02641 | 1/20 | 0.40 |
| ▸ | HPGDS | O60760 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.39 |
| ▸ | DRD2 | P14416 | 1/20 | 0.39 |
| ▸ | DRD4 | P21917 | 1/20 | 0.39 |
| ▸ | DRD3 | P35462 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1776882 | 1.00 | KDM2B (0.57) | KDM2BPOLBLTA4HHTR1AHTR1D | |
| SCHEMBL16034569 | 0.72 | KDM2B (1.00) | KDM2BKDM4C | |
| SCHEMBL13363854 | 0.72 | NPC1 (0.63) | MERTKNPC1RAB9A | |
| SCHEMBL12677853 | 0.72 | PDE10A (0.48) | POLBLTA4HHTR1AHTR1DHTR2A | |
| SCHEMBL24955627 | 0.71 | KDM2B (0.44) | KDM2BHPGDSNPC1RAB9APDE10A | |
| SCHEMBL22761664 | 0.70 | MERTK (0.44) | KDM2BPOLBLTA4HHTR1AHTR1D | |
| SCHEMBL1778699 | 0.70 | DRD2 (0.49) | HPGDSNPC1RAB9ADRD2DRD4 | |
| SCHEMBL1778701 | 0.70 | DRD2 (0.49) | HPGDSNPC1RAB9ADRD2DRD4 | |
| SCHEMBL2581577 | 0.69 | POLB (0.43) | POLBLTA4HHTR1AHTR1DHTR2A | |
| SCHEMBL2910946 | 0.68 | CYP2E1 (0.67) | HPGDSNPC1RAB9APDE10ADRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7943645-B2 | Piperidine compounds for use as orexin receptor antagonist | SMITHKLINE BEECHAM LIMITED (GB) | 2011-05-17 | — | — | US | disclosed |
| US-20090082390-A1 | PIPERIDINE COMPOUNDS FOR USE AS OREXIN RECEPTOR ANTAGONIST | SMITHKLINE BEECHAM P.L.C. | 2009-03-26 | — | — | US | disclosed |
| US-7423052-B2 | Piperidine compounds for use as orexin receptor antagoinst | SMITHKLINE BEECHAM P.L.C. (GB) | 2008-09-09 | — | — | US | disclosed |
| EP-1406897-B1 | COMPOUNDS | SMITHKLINE BEECHAM PLC (GB) | 2007-03-14 | — | — | EP | disclosed |
| US-20040215014-A1 | Piperidine compounds for use as orexin receptor antagonist | SMITHKLINE BEECHAM LIMITED (GB) | 2004-10-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090082390-A1 | PIPERIDINE COMPOUNDS FOR USE AS OREXIN RECEPTOR ANTAGONIST | HCRTR2, HCRTR1, OXTR | KDM2B 1313/4885POLB 4624/4885LTA4H 930/4885 |
| US-20040215014-A1 | Piperidine compounds for use as orexin receptor antagonist | HCRTR2, HCRTR1, OXTR | KDM2B 1106/4885POLB 4779/4885LTA4H 990/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.